There is more news about the drug recently approved in the treatment of multiple sclerosis. Further tests show now that the drug, called Antegren, may work twice as well as any other MS drug on the market, including the popular therapy - Avonex, which is made by the same company, Biogen IDEC, or Biotech
"This is going to be a major milestone for Biotech. Not really from a stock standpoint, but from a medical standpoint. This is probably one of the decade's most important therapies," says Jennifer Chao, with Deutsche Bank.
That's because there are about 400,000 patients in the US looking for a drug to get rid of the flare-ups that come with MS. The disease is debilitating and the flare-ups describe the random spells of downtime when symptoms like paralysis or vision loss get worse. Analysts are already predicting Antegren could become a multi billion dollar a year product. It will be marketed under the name Tysabri. For more information, ( click here ).